前列腺素脂微球制剂对1型糖尿病肾病患者尿β_2微球蛋白及尿转铁蛋白的影响  

Effect of Tubular Function in Diabetic Nephropathy Patients with Type1 Diabetes Mellitus

作　　者：任建如[1] 

机构地区：[1]江苏省常州市第一人民医院内分泌科,213000

出　　处：《齐齐哈尔医学院学报》2006年第16期1923-1924,共2页Journal of Qiqihar Medical University

摘　　要：目的观察前列腺素脂微球制剂(LipoPGE1)对糖尿病肾病肾小管功能影响,探讨前列腺素脂微球制剂防治糖尿病肾病机制。方法44例无高血压、持续有微量白蛋白尿的1型糖尿病患者被随机分为前列腺素脂微球制剂治疗组和常规治疗组。结果前列腺素脂微球制剂治疗3周后患者尿转铁蛋白(THP)增加了48.1%、尿β2微球蛋白(β2-MG)减少了36.3%,而常规治疗组无明显变化。结论前列腺素脂微球制剂对糖尿病肾病的肾小管有明显保护作用。Objective To observe the change of tubular function in diabetic nephropathy patients with type 1 diabetes mellitus with i.v.Lipo PGE_1.Methods 44 cases were divided into control group (23 cases) and Lipo PGE_1 group (21 cases),urineβ_2 -MG and urine THP were measured in each group. Results Urine THP was higher and urineβ_2 -MG was lower in Lipo PGE_1 group than those in the control group.Conclusions Lipo PGE_1 can protect tubular function.

关 键 词：1型糖尿病 糖尿病肾病 前列腺素脂微球制剂 尿Β2-MG 尿THP 

分 类 号：R[医药卫生]